Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14065337 | 0.79 | PIN1 (0.42) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL12466747 | 0.78 | MAPT (0.37) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9354810 | 0.76 | CALM1 (0.43) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL3429193 | 0.73 | LMNA (0.47) | MAPTKDM4EALDH1A1PIN1RAB9A | |
| SCHEMBL14065340 | 0.73 | ALDH1A1 (0.42) | MAPTPOLBMEN1KMT2AKDM4E | |
| SCHEMBL1191434 | 0.72 | HTT (0.47) | KMT2AALDH1A1CALM1NPC1 | |
| SCHEMBL8568534 | 0.72 | CYP19A1 (0.40) | MAPTPOLBSMN1; SMN2RIPK1CYP19A1 | |
| SCHEMBL31475345 | 0.71 | MAPT (0.47) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14782135 | 0.70 | POLB (0.49) | MAPTPOLBMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL25350969 | 0.70 | MAPT (0.42) | MAPTPOLBMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2443092-B1 | BICYCLIC AND TRICYCLIC COMPOUNDS AS KAT II INHIBITORS | PFIZER (US) | 2015-04-08 | — | — | EP | disclosed |
| CN-102482221-A | Bicyclic and tricyclic compounds as KATII inhibitors | PFIZER | 2012-05-30 | — | — | CN | disclosed |
| US-8183238-B2 | Bicyclic and tricyclic compounds as KAT II inhibitors | PFIZER INC. (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | PFIZER INC | 2010-12-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324043-A1 | Bicyclic And Tricyclic Compounds As KAT II Inhibitors | KAT2A, KAT2B, KAT6B | MAPT 258/4885POLB 287/4885MEN1 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.